Evidence map›Paper›PMID 37572284›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2023

Discriminating Immunorecognition Pathways Activated by RNA Nanostructures.

Leyla Danai, M Brittany Johnson, Kirill A Afonin

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 62% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Leyla DanaiNanoscale Science Program, Department of Chemistry, University of North Carolina at Charlotte, Charlotte, NC, USA.
M Brittany JohnsonDepartment of Biological Sciences, University of North Carolina at Charlotte, Charlotte, NC, USA.
Kirill A AfoninNanoscale Science Program, Department of Chemistry, University of North Carolina at Charlotte, Charlotte, NC, USA. kafonin@uncc.edu.
University of North Carolina at Charlotte · US

Funding

SMART NANPs: new molecular platform for communication with human immune system and modulation of therapeutic responsesR35GM139587 · NIGMS · UNIVERSITY OF NORTH CAROLINA CHARLOTTE · PI AFONIN, KIRILL A · 2021 to 2025
$1.8M
NIGMS NIH HHS R35 GM139587
6 · The paper itself

Abstract

Nucleic acid nanoparticles (NANPs) composed of therapeutic DNA, RNA, or a hybrid of both are increasingly investigated for their targeted and tunable immunomodulatory properties. By taking advantage of the NANPs' unique and relatively straightforward self-assembling behavior, nucleic acid sequences can be designed from the bottom-up and specifically tailored to induce certain immune responses in mammalian cells (Johnson et al., Nucleic Acids Res 48:11785-11798, 2020). Although not yet used in the clinic, functionalized NANPs display promising advantages to be included in therapeutic applications. By adjusting the chemical composition of a limited selection of NANPs all sharing the same physicochemical properties, it is demonstrated how substituting RNA strands for different chemical analogs can increase the thermodynamic and enzymatic stability of NANPs. Altering the composition of NANPs also determines the cellular mechanisms which initiate immune responses, therefore impacting the subcellular targeting and delivery efficiency.

Indexed as

NanoparticlesNanostructuresNucleic AcidsAnimalsDNAMammalsRNADNANucleic AcidsRNADNA analogsNANPsPattern recognition receptorsRetinoic acid inducible gene-1Targeted intracellular deliveryTherapeutic nucleic acids

Identifiers

PMID37572284
PMCPMC10482317
OpenAlexW4385785617

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.